TipRanks
Go Ultimate55% OFF

Compare Cipher Pharmaceuticals (PHE) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:PHECipher PharmaceuticalsEUR 8.10EUR 211.80M8.19-7.43%Moderate BuyUnlock the DE:PHE analyst price target with TipRanks PremiumDE:PHEUnlock the DE:PHE top-analyst price target with TipRanks Premium
TSE:GUDKnight TherapeuticsCAD 11.27CAD 1.11B76.6194.31%Strong BuyUnlock the TSE:GUD analyst price target with TipRanks PremiumDE:PHE vs TSE:GUDUnlock the TSE:GUD top-analyst price target with TipRanks Premium
TSE:MDPMedexus Pharmaceuticals IncCAD 4.93CAD 154.93M-46.2474.82%Moderate BuyUnlock the TSE:MDP analyst price target with TipRanks PremiumDE:PHE vs TSE:MDPUnlock the TSE:MDP top-analyst price target with TipRanks Premium
TSE:RXBiosyentCAD 17.09CAD 193.27M19.4258.24%Moderate BuyUnlock the TSE:RX analyst price target with TipRanks PremiumDE:PHE vs TSE:RXUnlock the TSE:RX top-analyst price target with TipRanks Premium
TSE:HLSHLS Therapeutics IncCAD 4.51CAD 139.52M-12.23-18.74%Moderate BuyUnlock the TSE:HLS analyst price target with TipRanks PremiumDE:PHE vs TSE:HLSUnlock the TSE:HLS top-analyst price target with TipRanks Premium
TSE:CRDLCardiol TherapeuticsCAD 1.62CAD 195.47M-4.715.88%Strong BuyUnlock the TSE:CRDL analyst price target with TipRanks PremiumDE:PHE vs TSE:CRDLUnlock the TSE:CRDL top-analyst price target with TipRanks Premium

Performance Comparison

-50%-25%0%25%50%75%100%125%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:PHECipher Pharmaceuticals8.10-0.90-10.00%
TSE:GUDKnight Therapeutics11.275.4392.98%
TSE:MDPMedexus Pharmaceuticals Inc4.932.1376.07%
TSE:RXBiosyent17.096.3058.46%
TSE:HLSHLS Therapeutics Inc4.51-0.99-18.00%
TSE:CRDLCardiol Therapeutics1.620.085.19%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts